SCOPUS 정보 검색 플랫폼

Volumn 143, Issue 3, 2012, Pages

Factors that predict response of patients with hepatitis C virus infection to Boceprevir

(18) Poordad, Fred a Bronowicki, Jeanpierre b Gordon, Stuart C c Zeuzem, Stefan d Jacobson, Ira M e Sulkowski, Mark S f Poynard, Thierry g Morgan, Timothy R h Molony, Cliona i Pedicone, Lisa D i Sings, Heather L i Burroughs, Margaret H i Sniukiene, Vilma i Boparai, Navdeep i Goteti, Venkata S i Brass, Clifford A i Albrecht, Janice K i Bacon, Bruce R j

a CEDARS SINAI MEDICAL CENTER (United States)

b UNIVERSITY HOSPITAL OF NANCY (France)

c HENRY FORD HOSPITAL (United States)

d UNIVERSITY HOSPITAL FRANKFURT (Germany)

e WEILL CORNELL MEDICAL COLLEGE (United States)

f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (United States)

g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS (France)

h VA LONG BEACH HEALTHCARE SYSTEM (United States)

i MERCK RESEARCH LABORATORIES (United States)

more..

Author keywords

Clinical Trial; Genetic; Prognostic Factors; Response to Therapy

Indexed keywords

BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; VIRUS LOAD;

EID: 84865494240 PISSN: 00165085 EISSN: 15280012 Source Type: Journal
DOI: 10.1053/j.gastro.2012.05.011 Document Type: Article

Times cited : (181)

References (14)

1
- 0037179698
- Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
- M.W. Fried, M.L. Shiffman, K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
- (2002) N Engl J Med , vol.347 , pp. 975-982
- Fried, M.W.¹ Shiffman, M.L.² Reddy, K.R.³

2
- 0035934568
- Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
- DOI 10.1016/S0140-6736(01)06102-5
- M.P. Manns, J.G. McHutchison, S.C. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
- (2001) Lancet , vol.358 , Issue.9286 , pp. 958-965
- Manns, M.P.¹ McHutchison, J.G.² Gordon, S.C.³ Rustgi, V.K.⁴ Shiffman, M.⁵ Reindollar, R.⁶ Goodman, Z.D.⁷ Koury, K.⁸ Ling, M.-H.⁹ Albrecht, J.K.¹⁰

3
- 70349292099
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
- D. Ge, J. Fellay, A.J. Thompson Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
- (2009) Nature , vol.461 , pp. 399-401
- Ge, D.¹ Fellay, J.² Thompson, A.J.³

4
- 23444460553
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
- DOI 10.1016/j.jhep.2005.04.009, PII S016882780500320X
- P. Ferenci, M.W. Fried, M.L. Shiffman Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin J Hepatol 43 2005 425 433 (Pubitemid 41111423)
- (2005) Journal of Hepatology , vol.43 , Issue.3 , pp. 425-433
- Ferenci, P.¹ Fried, M.W.² Shiffman, M.L.³ Smith, C.I.⁴ Marinos, G.⁵ Goncales Jr., F.L.⁶ Haussinger, D.⁷ Diago, M.⁸ Carosi, G.⁹ Dhumeaux, D.¹⁰ Craxi, A.¹¹ Chaneac, M.¹² Reddy, K.R.¹³

5
- 68249154875
- Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
- J.G. McHutchison, E.J. Lawitz, M.L. Shiffman Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
- (2009) N Engl J Med , vol.361 , pp. 580-593
- McHutchison, J.G.¹ Lawitz, E.J.² Shiffman, M.L.³

6
- 77953881002
- Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in hepatitis C virus-1 patients
- A.J. Thompson, A.J. Muir, M.S. Sulkowski Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in hepatitis C virus-1 patients Gastroenterology 139 2010 120 129
- (2010) Gastroenterology , vol.139 , pp. 120-129
- Thompson, A.J.¹ Muir, A.J.² Sulkowski, M.S.³

7
- 70349548852
- IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
- V. Suppiah, M. Moldovan, G. Ahlenstiel IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 11001004
- (2009) Nat Genet , vol.41
- Suppiah, V.¹ Moldovan, M.² Ahlenstiel, G.³

8
- 70349533037
- Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
- Y. Tanaka, N. Nishida, M. Sugiyama Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
- (2009) Nat Genet , vol.41 , pp. 1105-1109
- Tanaka, Y.¹ Nishida, N.² Sugiyama, M.³

9
- 84861570509
- Combined effects of different IL28B gene variants on the outcome of dual combination therapy in chronic HCV type 1 infection
- J. Fischer, S. Bhm, M. Scholz Combined effects of different IL28B gene variants on the outcome of dual combination therapy in chronic HCV type 1 infection Hepatology 55 2012 1700 1710
- (2012) Hepatology , vol.55 , pp. 1700-1710
- Fischer, J.¹ Bhm, S.² Scholz, M.³

10
- 79953173221
- Boceprevir for untreated chronic HCV genotype 1 infection
- F. Poordad, B. Bacon, S. Bruno Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
- (2011) N Engl J Med , vol.364 , pp. 1195-1206
- Poordad, F.¹ Bacon, B.² Bruno, S.³

11
- 79953176289
- Boceprevir for previously treated chronic HCV genotype 1 infection
- B. Bacon, S. Gordon, E. Lawitz Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
- (2011) N Engl J Med , vol.364 , pp. 1207-1217
- Bacon, B.¹ Gordon, S.² Lawitz, E.³

12
- 77955691994
- Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin
- N. Akuta, F. Suzuki, M. Hirakawa Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin Hepatology 52 2010 421 429
- (2010) Hepatology , vol.52 , pp. 421-429
- Akuta, N.¹ Suzuki, F.² Hirakawa, M.³

13
- 85058204756
- Predictors of consent to pharmocogenomics testing in the IDEAL study
- A. Jazwinski, P.J. Clark, A.J. Thompson Predictors of consent to pharmocogenomics testing in the IDEAL study Hepatology 54 2011 S54A
- (2011) Hepatology , vol.54
- Jazwinski, A.¹ Clark, P.J.² Thompson, A.J.³

14
- 80053545448
- Adherence to assigned dosing regimen and sustained virologic response among hepatitis C genotype 1 treatment-naive and peg/ribavirin treatment-failures treated with boceprevir plus peginterferon alfa-2b/ribavirin
- S.C. Gordon, E.J. Lawitz, B.R. Bacon Adherence to assigned dosing regimen and sustained virologic response among hepatitis C genotype 1 treatment-naive and peg/ribavirin treatment-failures treated with boceprevir plus peginterferon alfa-2b/ribavirin J Hepatol 54 2011 S173 S174
- (2011) J Hepatol , vol.54
- Gordon, S.C.¹ Lawitz, E.J.² Bacon, B.R.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.